An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

Discover a study that suggests that dual therapy could offer a safer and more effective approach to treating MASLD.

High levels of liver enzymes in your blood may sometimes indicate an underlying liver condition that requires medical ...

Researchers shed light on the "dark matter" of the gut, revealing a species of fungus that could potentially help counter ...

Researchers identified a rare variant on a single gene that appears to predispose patients to metabolic ...

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with ...

Mar. 11, 2025 — Metabolic dysfunction-associated steatohepatitis (MASH) is a polygenic disorder ... Novel Therapeutics of Nonalcoholic Fatty Liver Diseases Mar. 6, 2025 — Investigators have ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...